Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNETISMM-5: Elranatamab ± Daratumumab vs Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma
jRCT2041210098Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jan 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of elranatamab in multiple myeloma (MM) (6 arms), sponsored by Pfizer. Primary endpoints: Incidence of dose limiting toxicities in Part 1 Safety Lead-In, Progression-free survival in Part 2 and 1 more. Started Jan 2022; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2041210098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210098.